A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Legend Biotech Corp stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 50,268 shares of LEGN stock, worth $1.65 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
50,268
Previous 50,268 -0.0%
Holding current value
$1.65 Million
Previous $2.45 Million -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$43.55 - $59.88 $836,072 - $1.15 Million
19,198 Added 61.79%
50,268 $2.45 Million
Q2 2024

Jul 29, 2024

BUY
$39.5 - $57.22 $251,457 - $364,262
6,366 Added 25.77%
31,070 $1.38 Million
Q1 2024

Apr 25, 2024

BUY
$55.06 - $69.99 $366,974 - $466,483
6,665 Added 36.95%
24,704 $1.39 Million
Q4 2023

Jan 30, 2024

BUY
$57.25 - $69.74 $291,059 - $354,558
5,084 Added 39.24%
18,039 $1.09 Million
Q3 2023

Oct 25, 2023

SELL
$63.16 - $76.5 $262,492 - $317,934
-4,156 Reduced 24.29%
12,955 $870,000
Q2 2023

Aug 07, 2023

SELL
$46.28 - $75.01 $1,203 - $1,950
-26 Reduced 0.15%
17,111 $1.18 Million
Q1 2023

May 08, 2023

BUY
$43.42 - $57.37 $220,573 - $291,439
5,080 Added 42.13%
17,137 $826,000
Q4 2022

Feb 01, 2023

SELL
$38.8 - $55.46 $388 - $554
-10 Reduced 0.08%
12,057 $601,000
Q2 2022

Aug 09, 2022

SELL
$33.54 - $55.0 $344,153 - $564,355
-10,261 Reduced 45.96%
12,067 $664,000
Q1 2022

Apr 21, 2022

BUY
$31.02 - $48.18 $215,806 - $335,188
6,957 Added 45.26%
22,328 $811,000
Q4 2021

Feb 01, 2022

BUY
$41.14 - $56.98 $437,770 - $606,324
10,641 Added 224.97%
15,371 $716,000
Q3 2021

Nov 15, 2021

BUY
$35.31 - $50.56 $167,016 - $239,148
4,730 New
4,730 $239,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.